The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study

Tofacitinib (TOFA), a representative of a new class of targeted synthetic disease-modifying antirheumatic drugs (s-DMARD), is a promising drug for treating rheumatoid arthritis (RA) and other immune inflammatory diseases.Objective: to evaluate the efficiency and safety of therapy with TOFA in combin...

Full description

Bibliographic Details
Main Authors: D. E. Karateev, D. E. Abdulganieva, A. R. Babaeva, A. A. Baranov, L. P. Evstigneeva, O. N. Ivanova, G. V. Lukina, E. L. Luchikhina, V. I. Mazurov, A. S. Misiyuk, O. V. Semagina, A. E. Sizikov, V. N. Sorotskaya
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2017-03-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/732